307 studies found for:    Alemtuzumab
Show Display Options
Rank Status Study
1 Withdrawn Alemtuzumab and Rituximab in Aplastic Anemia
Condition: Aplastic Anemia
Intervention: Drug: Alemtuzumab and Rituximab
2 Terminated Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine Hydrochloride;   Biological: Alemtuzumab
3 Completed
Has Results
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: rituximab;   Drug: fludarabine phosphate
4 Completed Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
Condition: Kidney Transplantation
Interventions: Drug: Alemtuzumab;   Drug: Tacrolimus
5 Terminated
Has Results
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Campath-1H;   Drug: G-CSF;   Drug: GM-CSF;   Drug: BCNU;   Drug: Stem Cell Transplant;   Drug: Preparative Regimen for Allogenic Stem Cell Transplantation;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Campath;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Low dose total body irradiation
6 Recruiting Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Palifermin;   Drug: Alemtuzumab
7 Completed
Has Results
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Intervention: Biological: Alemtuzumab
8 Active, not recruiting Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Alemtuzumab
9 Completed Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Alemtuzumab (CAMPATH 1H) associated to G-CSF
10 Completed CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
11 Active, not recruiting A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
Condition: Leukemia
Interventions: Biological: Alemtuzumab;   Biological: Rituximab
12 Terminated
Has Results
Alemtuzumab + Rituximab Consolidation in CLL
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Rituximab;   Drug: Alemtuzumab
13 Active, not recruiting Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects
Condition: Multiple Sclerosis
Interventions: Drug: Alemtuzumab;   Drug: Alemtuzumab immunotherapy
14 Terminated
Has Results
Alemtuzumab and Pentostatin In T-cell Neoplasms
Conditions: Lymphoma;   Leukemia
Interventions: Drug: Pentostatin;   Drug: Alemtuzumab
15 Active, not recruiting Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
Conditions: Evidence of Liver Transplantation;   Rejection;   ALEMTUZUMAB/NATALIZUMAB [VA Drug Interaction]
Intervention: Drug: Alemtuzumab
16 Active, not recruiting CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: CHOP;   Drug: Alemtuzumab;   Procedure: Plasma Samples
17 Terminated Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
Condition: Leukemia
Intervention: Drug: Alemtuzumab
18 Active, not recruiting Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
Interventions: Biological: alemtuzumab;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: mycophenolate mofetil;   Drug: cyclosporine
19 Active, not recruiting Advanced MRI Measures of Repair in Alemtuzumab Treated Patients
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: MabCampath-1h
20 Unknown  Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Alemtuzumab and Rituximab combination

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years